Stock-Based Compensation and Employee Benefit Plans |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-Based Compensation and Employee Benefit Plans [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-Based Compensation and Employee Benefit Plans | Note 11 — Stock-Based Compensation and Employee Benefit Plans
2022 Omnibus Equity Incentive Plan
On April 29, 2022, the Company’s Board of Directors, and on June 8, 2022, the Company’s stockholders, adopted and approved the 2022 Omnibus Equity Incentive Plan (the “2022 Plan”), which provides for the grant of stock options, stock appreciation right awards, performance share awards, restricted stock awards, restricted stock unit awards, other stock-based awards and cash-based awards. As of September 30, 2026, there were 218,565 shares of Common Stock available to be granted under the Company’s 2022 Plan.
The Company’s stock compensation expense from continuing operations was $517 thousand and $508 thousand for the three months ended September 30, 2026 and 2025, respectively. The Company’s stock compensation expense from continuing operations was $1.7 million and $1.6 million for the nine months ended September 30, 2026 and 2025, respectively.
The Company’s stock compensation expense from discontinued operations was $ and a forfeiture of $nil for the three months ended September 30, 2026 and 2025, respectively. The Company’s stock compensation expense from discontinued operations was $ and a forfeiture of $20 thousand for the nine months ended September 30, 2026 and 2025, respectively.
Stock Options
For the nine months ended September 30, 2026, there were no options granted, exercised, or expired under the Company’s stock option plans. There were 75 options outstanding with a weighted average exercise price of $27 thousand as of both September 30, 2026 and December 31, 2025. There were unvested options as of September 30, 2026.
As of September 30, 2026, there was unrecognized compensation expense related to unvested options.
The following table summarizes information about options vested and exercisable at September 30, 2026:
Restricted Stock Units
Under the 2022 Plan, the Company may grant restricted stock units to employees, directors and officers. The restricted stock units granted generally vest equally over periods ranging from one to three years, subject to certain exceptions for directors. The fair value of restricted stock units is determined based on the closing market price of the Company’s Common Stock on the date of grant. Compensation expense related to the restricted stock units is recognized using a straight-line attribution method over the vesting period.
The following table presents restricted stock unit activity for the nine months ended September 30, 2026:
As of September 30, 2026, total unrecognized compensation expense related to unvested restricted stock units was $3.2 million, which is expected to be recognized over a weighted average period of 0.99 years. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||